HeartSciences is a medical technology company developing artificial intelligence-powered electrocardiogram (ECG) solutions to improve cardiac disease screening and detection. The company's core products include the MyoVista wavECG, a resting 12-lead ECG device that uses proprietary machine learning algorithms to detect heart conditions—such as diastolic dysfunction—that standard ECGs often miss, and the MyoVista Insights cloud platform that enables healthcare institutions to deploy multiple AI-ECG algorithms without replacing existing infrastructure. HeartSciences generates revenue through a "razor-and-razorblade" model combining upfront device sales with recurring revenue from proprietary electrode supplies for the wavECG device, and plans to add algorithm usage fees and subscriptions as its cloud platform offerings gain regulatory clearance. The company targets frontline healthcare settings including primary care clinics, emergency departments, and health systems worldwide, addressing a large diagnostic gap where millions of patients with heart disease go undetected by conventional screening tools.